Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparison of Buprenorphine-Naloxone and Extended-Release Naltrexone After Opioid Withdrawal Management

  • By

  • Heather E. Hsu

  • Sara Lodi

  • Shapei Yan

  • Benjamin J. Bovell-Ammon

  • Paul J. Christine

  • Alyssa S. Tilhou

  • Dana Bernson

  • Patricia Novo

  • Joshua D. Lee

  • John Rotrosen

  • Jane M. Liebschutz

  • Alexander Y. Walley

  • Marc R. Larochelle

  • July 14, 2026

Share

Clinical Scorecard: Comparison of Buprenorphine-Naloxone and Extended-Release Naltrexone After Opioid Withdrawal Management

At a Glance

CategoryDetail
ConditionOpioid Use Disorder
Key MechanismsBuprenorphine-naloxone and XR naltrexone are FDA-approved medications for opioid use disorder, aimed at reducing opioid use and improving treatment retention.
Target PopulationIndividuals 18 years or older discharged from voluntary medically managed opioid withdrawal programs.
Care SettingCommunity-based medically managed opioid withdrawal programs.

Key Highlights

  • Buprenorphine-naloxone and XR naltrexone are effective in managing opioid use disorder.
  • Observational studies suggest lower overdose rates with buprenorphine-naloxone compared to XR naltrexone.
  • The study utilized a target trial emulation framework to compare treatment outcomes.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of opioid use disorder based on clinical criteria.

Management

  • Initiation of buprenorphine-naloxone or XR naltrexone within 28 days of MMOW discharge.

Monitoring & Follow-up

  • Monitor for all-cause mortality and nonfatal opioid overdose within 24 weeks of discharge.

Risks

  • Increased overdose risk has been observed in XR naltrexone group compared to buprenorphine-naloxone.

Patient & Prescribing Data

Individuals with opioid use disorder discharged from medically managed withdrawal programs.

Treatment strategies include buprenorphine-naloxone and XR naltrexone, with considerations for patient history and eligibility.

Clinical Best Practices

  • Utilize a target trial emulation framework for observational studies.
  • Ensure comprehensive eligibility criteria to minimize bias in treatment comparisons.
  • Incorporate race and ethnicity data to adjust for structural factors affecting treatment outcomes.

Related Resources & Content

Original Source(s)

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment

  • by Heather E. Hsu, Sara Lodi, Shapei Yan, Benjamin J. Bovell-Ammon, Paul J. Christine, Alyssa S. Tilhou, Dana Bernson, Patricia Novo, Joshua D. Lee, John Rotrosen, Jane M. Liebschutz, Alexander Y. Walley, Marc R. Larochelle

  • July 14, 2026

Related Content

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

Ketamine for substance use disorders: a systematic review and meta-analysis